UNE-EN ISO 12417-1:2016
Superseded
View Superseded by
Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements (ISO 12417-1:2015)
Hardcopy , PDF
Spanish, Castilian, English
20-04-2016
27-11-2024
1.1 This international standard specifies requirements for vascular device-drug combination products (VDDCPs) based upon current technical and medical knowledge. VDDCPs are medical devices with various clinical indications for use in the human vascular blood system. A VDDCP incorporates, as an integral part,substance(s) which, if used separately, can be considered to be a medicinal substance or product (drugsubstance, drug product) but the action of the medicinal substance is ancillary to that of the device andsupports the primary mode of action (PMOA) of the device. With regard to safety, this international standardoutlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing,sterilization, packaging, and information supplied by the manufacturer. For implanted products, thisinternational standard should be considered as a supplement to ISO 14630, which specifies generalrequirements for the performance of non-active surgical implants. This international standard should also beconsidered as a supplement to relevant device-specific standards, such as the ISO 25539 series specifyingrequirements for endovascular devices. Requirements listed in this international standard also addressVDDCPs that are not permanent implants.Due to variations in the design of combination products covered by this international standard and due to the relatively recent development of some of these combination products, acceptable standardized in vitro tests results and clinical study results are not always available. As further scientific and clinical data become available, appropriate revision of this standard might be necessary.1.2 Delivery systems or parts of the delivery system are included in the scope of this standard if theycomprise an integral component of the vascular device and if they are drug-covered (e.g. drug-coveredballoon catheters and drug-covered guidewires).1.3 Devices whose PMOA is to provide a conduit for delivery of a drug, are excluded from the scope of thisinternational standard (e.g. infusion catheters), unless they contain a drug component that is intended to havean ancillary action to the device part (e.g. antimicrobial coated infusion catheter).1.4 Procedures and devices used prior to and following the introduction of the VDDCP (e.g. balloonangioplasty devices) are excluded from the scope of this standard if they do not affect the drug-relatedaspects of the device.1.5 This international standard is not comprehensive with respect to the pharmacological evaluation ofVDDCPs. Some information on the requirements of different national and regional authorities is given inAnnex Bof this international standard.1.6 Absorbable components of VDDCPs (e.g. coatings) are addressed by this international standard in theirconnection with drug-related aspects of the device. Degradation and other time-dependent aspects ofabsorbable implants and coatings are not addressed by this international standard.NOTE Development of Technical Specification ISO/TS 17137, Cardiovascular absorbable implants and ASTM WK35909, Standard Guide to Testing Absorbable Stents and Stent Grafts is currently ongoing.1.7 This international standard does not address issues associated with viable or non-viable biologicalmaterials such as tissues, cells, or proteins.1.8 This international standard does not address issues associated with active surgical implants (i.e.,implants that require power not generated by the human body or gravity).
| Committee |
CTN 91
|
| DocumentType |
Standard
|
| Pages |
66
|
| PublisherName |
Asociación Española de Normalización
|
| Status |
Superseded
|
| SupersededBy |
| Standards | Relationship |
| DIN EN ISO 12417-1:2016-02 | Equivalent |
| EN ISO 12417-1:2015 | Identical |
| ISO 12417-1:2015 | Identical |